Concepedia

Lorna Dean

LD

Statistics

Publications

2

Citations

57

H-Index

2

Active since

2019

Affiliations

Clinical Research Institute(Current)

University of North Carolina Health Care

University at Buffalo, State University of New York

Theravance Biopharma (United States)

Lorna Dean is an author at Clinical Research Institute specializing in pharmacotherapy, respiratory pharmacotherapy, and bronchodilator therapy.

Publications per year

2019–2019

2

Publications

2

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

James F. Donohue, Edward Kerwin, Sanjay Sethi et al. · Respiratory Medicine · 2019 · 38 citations

, , +14

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

James F. Donohue, Edward Kerwin, Sanjay Sethi et al. · Respiratory Research · 2019 · 19 citations · Full text

, , +17

1–2 of 2